We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Hutchison China MediTech

Acceptance of surufatintib China NDA in epNET

Lighthouse | 12 November 2019

Mereo BioPharma

Setrusumab set to advance

Lighthouse | 11 November 2019

MaxCyte

Third cohort in CARMA Phase I initiated

Lighthouse | 24 October 2019

Nexstim

Warrants to be topped up with share placement

Lighthouse | 22 October 2019

Nexstim

Q319 update shows therapy business momentum

Lighthouse | 16 October 2019

Nexstim

A possible new opportunity in severe depression

Update | 09 October 2019

MaxCyte

Editas deal marks sixth commercial licence

Update | 07 October 2019

Hutchison China MediTech

ESMO 2019: surufatinib epNET PFS benefit confirmed

Update | 03 October 2019

Mereo BioPharma

Entering an important 12 month period

Update | 19 September 2019

MaxCyte

Consistent solid delivery

Update | 19 September 2019
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
145 results found.